NCT03971253Completed
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3000 (actual)
- First submitted
- 30 May 2019
- Start date
- 2 Sept 2019
- Primary completion date
- 29 May 2026
- Lead sponsor
- Astellas Pharma Inc
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT03971253
What you commit to
- Study type: Observational
- Participants enrolled: 3000
- From 2 Sept 2019 to the primary completion date, 29 May 2026
- 47 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable.
Who the study is looking for
- All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
Sex: All · Does not accept healthy volunteers
Sites (47)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.